What is Avidity Biosciences?
Avidity Biosciences is a biopharmaceutical innovator dedicated to the development of a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs). By combining the specificity of monoclonal antibodies with the precision of oligonucleotide-based therapies, the company aims to overcome the historical delivery challenges associated with RNA-based treatments. Its expanding pipeline currently targets high-unmet-need areas, including cardiology and immunology, supported by both internal research initiatives and high-value industry partnerships. The firm's market position is defined by its unique technological moat and its ability to attract top-tier life sciences investors.
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised a total of $1.6B across 8 funding rounds:
Series A
$9.1M
Debt
$6M
Series B
$16M
Series C
$100M
Stock Offering
$259M
Share Placement
$144M
Stock Offering
$461M
Stock/Share Issuance
$600M
Series A (2014): $9.1M, investors not publicly disclosed
Debt (2014): $6M led by TPG Biotech, Partner Fund Management, L.P, and Brace Pharma
Series B (2016): $16M supported by EcoR1 Capital, Takeda Ventures, Inc., Moore Venture Partners, Tavistock Life Sciences, BracePharma, Alethea Capital, Alexandria Real Estate Equities, and F-Prime Capital
Series C (2019): $100M featuring Alethea Capital, EcoR1 Capital, Eli Lilly and Company, CureDuchenne, Takeda Ventures, ST Pharm, Cormorant Asset Management, RTW Investments, Partner Fund Management, LP, Alexandria Venture Investments, Boxer Capital, Logos Capital, Brace Pharma Capital, and Perceptive Advisors LLC
Stock Issuance/Offering (2020): $259M, investors not publicly disclosed
Share Placement (2021): $144M, investors not publicly disclosed
Stock Issuance/Offering (2024): $461M, investors not publicly disclosed
Stock/Share Issuance (2025): $600M, investors not publicly disclosed
Key Investors in Avidity Biosciences
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, aiming to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation.
Takeda Ventures, Inc.
The venture arm of Takeda Pharmaceutical Company, focusing on research and development across gastroenterology, oncology, neuroscience, and rare diseases.
Brace Pharma Capital
An investment firm focused on innovative therapies for diseases that have significant unmet medical needs and limited treatment options.
What's next for Avidity Biosciences?
With the recent infusion of $600M, Avidity Biosciences is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The strategic focus will likely center on advancing its lead AOC candidates through late-stage clinical trials while simultaneously scaling its manufacturing and discovery capabilities. As the company matures, the emphasis will shift toward regulatory milestones and potential commercialization strategies, ensuring that its novel therapeutic modalities can reach patients suffering from rare and chronic conditions. The firm remains a focal point for investors seeking exposure to the next generation of genetic medicine.
See full Avidity Biosciences company page
